Hims and Hers Weight Loss in 2026: What Changed After the FDA Crackdown

In August 2025, Hims & Hers had 418,000 weight loss customers and compounded GLP-1 revenue was on pace to eclipse $225 million for the year. They ran two Super Bowl commercials. They were the face of the affordable weight loss revolution.

Six months later, the picture looks dramatically different. Novo Nordisk sued them. The FDA issued warnings about their compounded semaglutide. Their $49 oral GLP-1 pill was pulled days after launch. And in March 2026, Hims struck a deal with Novo Nordisk that fundamentally changes what the platform offers — and what it costs.

If you're currently a Hims or Hers weight loss customer, or considering becoming one, here's what you need to know.

The Timeline: How It All Unraveled

What Hims & Hers Looks Like Now

The current Hims/Hers weight loss landscape is a patchwork of old and new. Oral weight loss kits — combinations of metformin, bupropion, and naltrexone (not GLP-1 medications) — still start at $69 per month on a 10-month prepaid plan. These are the non-GLP-1 options that remain unchanged and represent Hims' most affordable weight loss offering.

Brand-name medications are now prominently listed. Ozempic appears at $1,799 per month cash price, Wegovy at $1,999, and Mounjaro at $1,899. These numbers reflect retail pricing — actual costs will be lower for patients with insurance coverage, and Hims is expected to offer competitive pricing through its Novo Nordisk partnership, though the exact negotiated rates aren't fully public yet.

Compounded injectable GLP-1s remain available in limited capacity at the previous $199 per month price point, but Hims has signaled these will be phased out. The company's CEO acknowledged that most compounded GLP-1 customers will need to transition to brand-name options or alternatives.

What This Means for the Broader Market

The Hims/Novo Nordisk settlement isn't just about one company. It signals the direction of the entire compounded GLP-1 industry. With the FDA shortage declaration officially over, the legal basis for mass compounding GLP-1 medications is narrower than it was in 2024–2025. Smaller compounding pharmacies and telehealth platforms are watching closely to see if Novo Nordisk and Eli Lilly pursue similar legal action against other providers.

That said, compounded GLP-1 medications haven't disappeared. Providers using 503B-licensed pharmacies that compound for individual patient prescriptions (rather than mass-produced bulk products) continue to operate under existing pharmacy law. The key distinction is between pharmacies compounding genuine individualized prescriptions and those producing commercial-scale product runs that look more like unlicensed drug manufacturing.

Your Options If You're Affected

If You Have Good Insurance Coverage

The Novo Nordisk price cuts and the Wegovy pill launch have made brand-name GLP-1s more accessible than at any point in the past two years. Programs like Calibrate and Ro Body specialize in insurance navigation and can often bring GLP-1 copays down to $25 per month or less. If your commercial insurance covers weight loss medications, this may actually work out cheaper than compounded options once you factor in prior authorization assistance.

If You're Paying Cash and Want to Stay Affordable

Several compounded GLP-1 providers continue to operate with transparent pricing, established pharmacy partnerships, and no indication of disruption. These providers typically work with individual prescriptions through licensed compounding facilities rather than the mass-production model that drew FDA scrutiny:

If You Want Non-GLP-1 Alternatives

Hims' $69 per month oral weight loss kits remain available and unaffected by the GLP-1 regulatory changes. These combine medications like metformin, bupropion, and naltrexone that work through different mechanisms. While the weight loss is more modest (typically 5–8% of body weight versus 15–22% with GLP-1s), the cost is substantially lower and the regulatory environment is stable.